Stock ALZCUR ALZECURE PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 12:20:21 15/05/2024 BST 		5-day change 1st Jan Change
1.785 SEK +0.28% Intraday chart for AlzeCure Pharma AB 0.00% -42.60%
05-14 AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors CI
04-25 AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 154.8 342.2 224.7 257 193.1 110.5 -
Enterprise Value (EV) 1 154.8 342.2 183 257 164 68.01 110.5
P/E ratio -3.04 x -4.79 x -2.89 x -3.51 x - 5.93 x -1.62 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - 1,841,915 x
EV / Revenue - - - - - - 1,841,915 x
EV / EBITDA - - -2.37 x - -4.34 x -1.46 x -15.8 x
EV / FCF - - - - 53.6 x 4 x -1.7 x
FCF Yield - - - - 1.86% 25% -58.8%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 37,766 37,766 37,766 62,087 62,087 62,087 -
Reference price 2 4.100 9.060 5.950 4.140 3.110 1.780 1.780
Announcement Date 28/02/20 26/02/21 24/02/22 24/02/23 27/02/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - - - - - - 0.00006
EBITDA 1 - - -77.35 - -37.79 -46.5 -7
EBIT 1 - - -77.93 - -38.26 -46.5 -7
Operating Margin - - - - - - -11,666,666.67%
Earnings before Tax (EBT) 1 - - -77.78 - -37.17 -46.5 -7
Net income 1 -50.86 -71.37 -77.78 -56.24 -37.17 -46.5 -7
Net margin - - - - - - -11,666,666.67%
EPS 2 -1.350 -1.890 -2.060 -1.180 - 0.3000 -1.100
Free Cash Flow 1 - - - - 3.057 17 -65
FCF margin - - - - - - -108,333,333.33%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 28/02/20 26/02/21 24/02/22 24/02/23 27/02/24 - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 - - 41.7 - 29.1 42.5 -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - - 3.06 17 -65
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - 0.05 - - - -
Capex / Sales - - - - - - -
Announcement Date 28/02/20 26/02/21 24/02/22 24/02/23 27/02/24 - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALZECURE PHARMA AB Stock AlzeCure Pharma AB
-42.60% 10.21M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.33% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.11% 106B
BIONTECH SE Stock BioNTech SE
-12.56% 22.24B
ARGENX SE Stock argenx SE
-3.64% 21.25B
GENMAB A/S Stock Genmab A/S
-5.61% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.86% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.57% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-26.24% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALZCUR Stock
  4. Financials AlzeCure Pharma AB